Attorney Docket No.: PB60402USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bailey et al. Confirmation No.: 4112 Serial No.: 10/564,931 Group Art Unit: 1625 Filing Date: January 17, 2006 Examiner: (not yet assigned) For: SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR §1.97. [X] Copies of the references are attached. Copies of the references were submitted in parent application Serial No.

the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. (37 CFR §1.97(b)).

OR

The Information Disclosure Statement submitted because his being filed.

[] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR §1.114. (37 CFR §1.97(b)(4)).

- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in §1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
 - (1) a final Office Action under §1.113 or
 - (2) a Notice of Allowance under §1.311, whichever occurs first.

Applicant hereby certifies that each item of information contained in this [] Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Applicant elects the option to pay the fee set forth in 37 CFR §1.17(p) for submission of an Information Disclosure Statement under §1.97(c) (\$180.00). C. The Information Disclosure Statement transmitted herewith is being filed after a final Office Action under §1.113, or a Notice of Allowance under §1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No. In accordance with the requirements of 37 CFR §1.97(d): [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. OR Applicant hereby certifies that no item of information contained in this [] Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; and The petition fee set forth in §1.17(i)(1) (\$180.00) is submitted herewith. Please charge any required fees to Deposit Account No. <u>07-1392</u>. A duplicate copy of this paper is attached. Respectfully Submitted, Bonnie L. Deppenbrock Attorney of Record Registration No. 28,209

Date: <u>3 August 200</u> Customer No.23347 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Attorney Docket No.: PB60402USw

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1577 Facsimile: (919) 483-7988